A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

NCT03947255 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

12

Enrollment

INDUSTRY

Sponsor class

Stopped Study stopped early due to low patient accrual.

Conditions

Hodgkin Lymphoma
Peripheral T Cell Lymphoma
Anaplastic Large Cell Lymphoma

Interventions

DRUG: brentuximab vedotin

Sponsor

Seagen Inc.